drugset / Trial / NCT01022671
Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy
Phase 2
Completed
52 enrolled
Chong Kun Dang Pharmaceutical
Asan Medical Center · collabSamsung Medical Center · collabSeoul National University Hospital · collabUlsan University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small cell lung cancer patients previously treated with chemotherapy. The usefulness of the this regimen is evaluated by response rate, median survival time, progression free survival and duration of response.
Timeline
- Start
- 2009-09
- Primary completion
- 2010-02
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belotecan | Small molecule | 3 mg/m2 | — |